Source comparison
CJC-1295 No DAC & Ipamorelin Myths: Research Peptide Comparison
CJC-1295 no DAC has a multi-day half-life Plasma half-life is approximately 30 minutes; clears within 2–3 hours Published pharmacokinetic data from Phase 1 trials (Teichman et al., 2006) Dosing intervals >6 hours miss GH secretion peaks entirely; null results
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC has a multi-day half-life
- Plasma half-life is approximately 30 minutes; clears within 2–3 hours
- Published pharmacokinetic data from Phase 1 trials (Teichman et al., 2006)
- Dosing intervals >6 hours miss GH secretion peaks entirely; null results attributed to compound failure rather than timing error
- Ipamorelin is orally bioavailable
- Oral bioavailability is effectively zero; requires subcutaneous or IV administration
- Peptide bond hydrolysis in gastric acid; no published data supporting oral efficacy
- Wasted compound in oral dosing attempts; protocol delays from route-of-administration errors
- Reconstituted peptides are stable at room temperature for weeks
- Stability degrades significantly above 8°C; 28-day refrigerated limit assumes continuous 2–8°C storage
- USP monographs for peptide stability; temperature-controlled storage standards
- Batch losses from undetected degradation; false negatives in efficacy studies
- Combining CJC-1295 no DAC and Ipamorelin creates synergistic (multiplicative) effects
- Combined effects are additive, not synergistic; GH secretion equals sum of individual contributions
- Comparative GH secretion studies in healthy volunteers
- Underdosing based on synergy assumptions; confounded results from empirical dose escalation
- DAC and non-DAC CJC-1295 are functionally interchangeable
- DAC modification extends half-life from 30 minutes to 6–8 days; dosing and timing protocols are completely different
- Structural pharmacology of Drug Affinity Complex modifications
- Protocol failures from using DAC dosing schedules with non-DAC compounds